CD8A and viral infectious disease: Another study on infant acute lung injury during viral infection showed that there is a correlation between a reduced CD4+ to CD8+ ratio and lung damage and so brings credence to the clinical trials involving MSCs as a therapeutic for COVID-19 infections [50].